Skip to main content

Table 1 Timing of omalizumab-associated anaphylaxis*

From: Omalizumab: Practical considerations regarding the risk of anaphylaxis

Timing of the reaction

Number of Episodes

 

1 st , 2 nd or 3 rd Omalizumab dose, n

4 th Omalizumab dose or later, n (%)

Total

< 30 minutes

11

5

16

30 - 60 minutes

6

1

7

1 - 2 hours

5

0

5

Total 0 - 2 hours

22

6

28

2 - 12 hours

4

1

5

> 12 hours

3

0

3

Overall Total

29

7

36

  1. *Data represent 36 of 41 identified episodes of anaphylaxis; timing was not known for the remaining 5 episodes. The 41 episodes were among 35 patients. During the period of review, there were 39,510 patients being treated with omalizumab.